Latest Ratios: P/E Ratio -1.0x · EV/EBITDA N/A · ROE -101.5%. (2007–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $26M | $8M | $8M | $7M | $2M | $295M | $139M | $13M | $10M | $35M | $58M |
| Enterprise Value | $21M | $3M | $-1666590 | $17M | $5M | $251M | $117M | $34M | $19M | $52M | $61M |
| P/E Ratio → | -0.95 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 65.92 | 20.03 | 35.93 | — | 1.20 | 124.58 | 85.11 | 6.66 | 21.55 | 88.21 | 61.50 |
| P/B Ratio | 1.18 | 0.54 | 0.38 | 0.49 | 0.04 | 2.72 | 2.46 | 5.47 | 0.59 | 3.90 | 2.42 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 7.34 | -7.41 | — | 2.84 | 105.74 | 71.55 | 16.80 | 42.15 | 131.80 | 64.05 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | — | -101.2% | 38.3% | 57.1% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -4650.5% | -4650.5% | -7392.9% | — | -1576.3% | -1312.1% | -854.9% | -782.4% | -3204.3% | -3622.8% | -1043.6% |
| Net Profit Margin | -4594.3% | -4594.3% | -11069.8% | — | -2674.7% | -978.8% | -1003.6% | -871.8% | -3627.3% | -3688.3% | -1030.0% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -101.5% | -101.5% | -135.7% | -164.9% | -58.6% | -28.1% | -55.7% | -189.0% | -128.4% | -88.2% | -55.4% |
| ROA | -70.8% | -70.8% | -71.2% | -92.5% | -40.9% | -19.2% | -26.3% | -47.8% | -40.7% | -33.2% | -30.5% |
| ROIC | -130.5% | -130.5% | -68.0% | -48.0% | -34.1% | -47.5% | -36.6% | -49.1% | -41.5% | -40.7% | -52.6% |
| ROCE | -88.6% | -88.6% | -74.7% | -66.2% | -28.4% | -27.1% | -24.1% | -46.3% | -37.9% | -34.3% | -32.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.24 | 0.24 | 0.21 | 1.11 | 0.41 | 0.30 | 0.58 | 10.13 | 1.55 | 2.83 | 1.06 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.34 | -0.46 | 0.63 | 0.05 | -0.41 | -0.39 | 8.33 | 0.57 | 1.93 | 0.10 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -85.68 | -85.68 | -88.78 | — | — | -12.62 | -5.67 | -8.26 | -7.41 | -7.37 | -12.21 |
Net cash position: cash ($9M) exceeds total debt ($4M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.59 | 1.59 | 4.08 | 1.22 | 1.48 | 15.74 | 11.79 | 1.39 | 8.00 | 4.26 | 10.43 |
| Quick Ratio | 1.59 | 1.59 | 4.08 | 1.22 | 1.35 | 15.74 | 11.64 | 1.39 | 8.00 | 4.25 | 10.43 |
| Cash Ratio | 1.41 | 1.41 | 3.70 | 0.34 | 1.10 | 14.59 | 10.53 | 1.28 | 7.83 | 4.02 | 10.05 |
| Asset Turnover | — | 0.02 | 0.01 | — | 0.02 | 0.02 | 0.02 | 0.07 | 0.01 | 0.01 | 0.02 |
| Inventory Turnover | — | — | — | — | 0.97 | 54.15 | 0.88 | — | — | — | — |
| Days Sales Outstanding | — | 95.81 | 1156.64 | — | 1181.79 | 850.69 | 1253.21 | 17.54 | 61.66 | 162.12 | 233.32 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.1% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.1% | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $10M | $4M | $612250 | $17442 | $391240 | $125590 | $37852 | $21262 | $17822 | $16194 |
Capital exhaustion and dilution
According to current market data, iBio trades at a price-to-sales ratio of 65.92, which appears to reflect speculative interest in its proprietary platform rather than the company's minimal $400,000 TTM revenue, suggesting that investors are pricing the stock as a high-risk option on future clinical or commercial success.
The extreme P/S multiple indicates that the market is not valuing the company based on its current manufacturing output or service revenue. This valuation level warrants caution, as it implies an expectation of significant future growth that remains unproven by the company's historical financial performance.
Based on reported figures, iBio's ROIC has consistently remained in negative territory, reaching -14.1% in 2026Q3, which highlights the company's ongoing struggle to generate positive returns on the capital invested into its plant-based protein expression platform and associated research and development programs.
The negative trend in ROIC suggests that every dollar of capital deployed is currently destroying shareholder value rather than compounding it. This persistent decay in returns is a direct consequence of high fixed costs and R&D spending that have yet to be offset by meaningful commercial revenue.
As reported in financial statements, the company's DPO has fluctuated significantly, reaching 1024 days in 2026Q3, which suggests that iBio is heavily reliant on extended payment terms with suppliers to manage its liquidity, rather than generating cash through efficient operational turnover or rapid service delivery.
The lack of meaningful asset turnover, coupled with extreme DPO figures, indicates that the company's working capital management is driven by necessity rather than operational efficiency. Investors should monitor whether these extended payment terms are sustainable or if they represent a hidden strain on supplier relationships.
While the company maintains a low debt-to-equity ratio of 0.03 as of 2026Q3, this appears to be a function of its reliance on equity-based financing rather than a sign of financial strength, as the lack of debt service capacity is evidenced by consistently negative interest coverage ratios.
The absence of significant debt is a positive for avoiding restrictive covenants, but it does not mitigate the fundamental risk of the company's high cash burn. The negative interest coverage ratio confirms that the company is not generating sufficient operating income to support even minimal debt obligations.
Investors frequently misapply the P/B ratio of 1.18 to iBio, failing to recognize that the book value is heavily inflated by accumulated capital raises rather than productive, revenue-generating assets, which obscures the reality that the company's core manufacturing facility may hold little market value in a liquidation scenario.
Using P/B as a valuation floor is misleading for a company with a $354.7 million accumulated deficit. A more appropriate metric for this business model would be the cash runway relative to the quarterly burn rate, as the company's survival depends on liquidity rather than the accounting value of its assets.
Includes 30+ ratios · 19 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IBIO stock.
iBio, Inc.'s current P/E ratio is -1.0x. This places it at the 50th percentile of its historical range.
iBio, Inc.'s return on equity (ROE) is -101.5%. The historical average is -106.4%.
Based on historical data, iBio, Inc. is trading at a P/E of -1.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
iBio, Inc. has 100.0% gross margin and -4650.5% operating margin.